Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

UK ‘difficult’ operating environment says Merck boss after £1bn London site axed

Last week, Merck’s business in the UK and Europe, MSD, said it will move its life sciences operation to the US, impacting around 125 British jobs.

Evening Standard

Eli Lilly To Invest $5 Billion In New Virginia Manufacturing Facility To Support Cancer Drugs Manufacturing

Eli Lilly and Co. (NYSE:LLY) announced on Tuesday that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County.

Benzinga

Who benefits if NHS drug prices soar? Donald Trump and big pharma. Just one more way he’s menacing Britain

The NHS needs cheap drugs, and our economy needs a thriving pharma industry. The president threatens both – no wonder Labour is grovelling to him, says Guardian columnist Polly Toynbee

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Big pharma firms have paused nearly £2bn in UK investments this year

Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears

The Guardian - UK

Pharmacy leaders issue warning over ‘dangerous’ medicine delays

One pharmacist reported their patients waiting more than a week for a medication for bipolar and schizophrenia

The Independent UK

The Guardian view on Merck’s exit: Britain’s biopharma strategy stalls in the face of China’s rise

Editorial: The industry’s retreat from the UK reflects a deeper shift about how Beijing is rewriting the rules of innovation

The Guardian - UK

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit

The U.K.-based AstraZeneca Plc (NASDAQ:AZN) paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

ATyr Pharma Stock Sinks, Plans FDA Review After Mixed Phase 3 Results

Biotech firm aTyr Pharma Inc. (NASDAQ:ATYR) plummeted over 81% at last check on Monday, with a session volume of 34.7 million compared to the average volume of 4.83 million as per data from Benzinga Pro.

Benzinga

Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs

The U.K. faces a growing risk of losing pharmaceutical investment. That’s according to Oxford professor John Bell, a scientist who was involved in coordinating government and industry efforts during the COVID-19 vaccine rollout.

Benzinga

Eli Lilly Loses Appeal Over Medicaid Drug Pricing Fraud Case

A federal appeals court has upheld a $183.7 million judgment against Eli Lilly and Co. (NYSE:LLY), rejecting the drugmaker's attempt to overturn a whistleblower lawsuit that accused it of defrauding Medicaid.

Benzinga

Britain’s biggest company AstraZeneca pauses £200m investment into Cambridge site

The investment had been set to create 1,000 jobs

The Independent UK

AstraZeneca pauses £200m investment in Cambridge research site

Decision means none of drugmaker’s much-trumpeted £650m UK investment package is currently proceeding

The Guardian - UK

Jim Cramer Says Johnson & Johnson Stock Could Power Through $200 Next

Despite ongoing legal battles related to its talc products, Johnson Johnson (NYSE:JNJ) stock has climbed over 23% year-to-date.

Benzinga

Exclusive: Lutnick says Trump will force drugmakers to lower prices

Trump's efforts include reshaping drug prices through threats and public shaming.

Axios

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores

A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking’s Momentum scores over the past week alone.

The Guardian - UK

Britain is ‘a terrible place’ to sell medicines, says drug firm executive

Sanofi’s market access chief urges ministers to come up with a roadmap to raise spending on new treatments

Benzinga

Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug

Revolution Medicines, Inc. (NASDAQ:RVMD) stock is trading higher after the company shared updates from its Daraxonrasib Phase 1 trials on Wednesday.

The Guardian - UK

UK must heed Sir John Bell’s big pharma investment warning

Instead of making silly statements the government needs to look at why Merck has scrapped its £1bn research centre

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Why Is AbbVie Stock Trading Higher On Thursday?

AbbVie Inc. (NYSE:ABBV) stock is trading higher on Thursday following an SEC filing that settled litigation with all generic manufacturers, which filed abbreviated new drug applications with the U.S. Food and Drug Administration for generic versions of upadacitinib tablets, marketed by the company as Rinvoq.

The Independent UK

Pharma giant ditches £1bn London research hub and says UK ‘is not internationally competitive’

Merck, known as MSD in Europe, criticised the UK’s business environment despite the government saying it has become ‘the most attractive place to invest in the world’

The Guardian - UK

Big pharma will stop investing in UK, top scientist warns after Merck’s £1bn exit

Comments by former professor of medicine at Oxford follow scrapping of planned London research centre

Evening Standard

Merck scraps £1bn London expansion as report warns UK drugs sector ‘losing out’

UK pharmaceutical sector ‘risks losing investment to other countries’.

Benzinga

BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) on Wednesday released topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated that BXCL501 had continued effects and consistent benefit with repeat dosing.

Benzinga

Synopsys Shares Are Trading Lower Wednesday: What's Going On?

Synopsys, Inc. (NASDAQ:SNPS) shares are trading lower Wednesday after the company reported worse-than-expected financial results and issued fourth quarter adjusted earnings per share guidance below estimates on Tuesday after the market closed. Also, the company cut its fiscal-year 2025 adjusted earnings per share guidance below estimates.

The Guardian - UK

US drugmaker Merck scraps £1bn London research centre and cuts 125 science jobs

New blow to UK’s key life science sector as industry body says country is losing ground on investment and research

1 … 13 14 15 16

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.